News

Pharmabiz4d
Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent
Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent: Wayne, Pennsylvania Saturday, June 21, 2025, 13:00 Hrs [IST] Palvella Therapeutics Inc, a clinical-sta ...
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 ...
Understanding Metastatic Renal Cell Carcinoma: Doctor explains how cancer spreads, signs and treatment options
A doctor breaks down metastatic renal cell carcinoma, explaining how the cancer spreads and discussing emerging treatment ...
Yahoo Finance7d
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - Yahoo Finance Canada
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella ...
Nasdaq7d
Palvella Therapeutics Secures Patent for QTORIN™ Rapamycin, Strengthening Intellectual Property Strategy Through 2038 - Nasdaq
Potential Positives. Palvella has secured a new U.S. patent (No. 12,329,748) for QTORIN™ rapamycin, enhancing its intellectual property portfolio and reinforcing its exclusivity strategy.
manilatimes8d
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
New intellectual property builds on Palvella's multi-layered exclusivity strategy. Patent term expected through at least 2038. WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella ...